LNCD(SH:600739) Shang Hai Zheng Quan Bao·2026-01-26 19:51Core Viewpoint - Liaoning Chengda Co., Ltd. plans to establish a biopharmaceutical investment fund in collaboration with its subsidiaries to enhance its competitiveness and capitalize on market opportunities in the healthcare sector [7][11][38]. Group 1: Investment Fund Establishment - The company intends to set up a biopharmaceutical industry investment fund with a total scale not exceeding 1 billion yuan, with an initial scale of 502 million yuan [7][11]. - The fund will focus on the life and health sector, particularly in areas such as innovative drugs, vaccines, and medical services [18][38]. - The fund's structure includes contributions from various subsidiaries, with Liaoning Chengda contributing 100 million yuan, representing approximately 19.92% of the initial fund size [8][11]. Group 2: Investment Strategy and Management - The fund will be managed by Chengda Coastal Industry (Dalian) Fund Management Co., Ltd., which is a wholly-owned subsidiary of the company [14][22]. - The investment strategy includes direct investments in high-quality projects and potential collaborations with other professional investors [18][19]. - The fund aims to achieve returns through strategic investments and timely exits from projects [19][20]. Group 3: Subsidiary Establishment - Liaoning Chengda's subsidiary, Chengda Biological Co., Ltd., plans to establish a wholly-owned subsidiary named Chengda Biological Innovation Pharmaceutical Co., Ltd. with a registered capital of 1 billion yuan [42][44]. - The investment will focus on innovative drug research and development, project acquisitions, and building a professional operational system [44][50]. - This move is part of the company's strategy to diversify its business and enhance its resilience against market fluctuations [50][52].